Non-Relapse Mortality in TP53-Mutated MDS/AML - a Multi-Center Collaborative Study
Byrne M, Kurian T, Patel D, Tamari R, Hong S, Abdelhakim H, Klein V, Rojas P, Madhavan R, Kent A, Logan A, Lee C, Husnain M, Manning B, Tschernia N, Dias A, Margalski D, Goldenson B, Byrne N, Chen H, Petrova-Drus K, Sengsayadeth S, Goodman A, Howard D, Wood W, Gill S, Jimenez A, Gutman J, Gowda L, Metheny L, Bhatnagar B, Hamilton B, Mishra A, Savona M. Non-Relapse Mortality in TP53-Mutated MDS/AML - a Multi-Center Collaborative Study. Blood 2021, 138: 2922. DOI: 10.1182/blood-2021-154151.Peer-Reviewed Original ResearchNon-relapse mortalityMDS/AMLChronic GVHDPost-HCT mortalityPost-HCT relapseOverall survivalRelapse/progressionShorter overall survivalBM chimerismComplex karyotypeImproved OSMyeloablative conditioningHigher KPSMultivariate analysisSecondary MDS/AMLAdvisory CommitteeLarge multi-institutional cohortMDS/AML patientsMulti-center collaborative studyLow NRM ratePost-HCT outcomesAllogeneic HCT recipientsSpeakers bureauYear overall survivalInferior overall survival